Walter M. Stadler, M.D.
Fred C. Buffett Professor of Medicine
Director, Genitourinary Program
Associate Dean for Clinical Research
Dr. Walter Stadler is an expert in prostate, kidney, bladder, and testicular cancers. He concentrates on the use of chemotherapy, immunotherapy, anti-angiogenic therapy, and molecularly targeted therapy for patients with locally advanced or metastatic disease.
His research focuses on the development of new treatments for these cancers as well as the development of molecular and imaging markers for predicting response to anti-angiogenic therapies. He is co-leader for a National Cancer Institute (NCI) funded SPORE program in prostate cancer, which funds translational research in this disease, and directs the NCI funded University of Chicago Phase II Consortium, which is a collaborative academic/community partnership to conduct early phase oncology clinical trials.
Dr. Stadler has authored and co-authored more than 130 articles in medical journals such as Cancer Research and the Journal of Clinical Oncology, in addition to more than 85 book chapters, reviews, letters, and editorials. He is an active member of several committees and boards, including the medical advisory board of the Kidney Cancer Association and the editorial board of UpToDate in Oncology, an information source for oncologists.